Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/billing-for-wallet-shock-digbijay-mishra-4674632/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/billing-for-wallet-shock-digbijay-mishra-4674632/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/billing-for-wallet-shock-digbijay-mishra-4674632/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/billing-for-wallet-shock-digbijay-mishra-4674632/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f37491186a0-trace').style.display = (document.getElementById('cakeErr67f37491186a0-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f37491186a0-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f37491186a0-code').style.display = (document.getElementById('cakeErr67f37491186a0-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f37491186a0-context').style.display = (document.getElementById('cakeErr67f37491186a0-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f37491186a0-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f37491186a0-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26594,
		&#039;title&#039; =&gt; &#039;Billing for wallet shock -Digbijay Mishra&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;
     &lt;br /&gt;
    At present, only branded drugs are mandated for this in US market&lt;br /&gt;
     &lt;br /&gt;
    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;
     &lt;br /&gt;
    Major Indian generic drug firms make at least half their revenue from the US market
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Business Standard, 24 November, 2014, http://www.business-standard.com/article/companies/billing-for-wallet-shock-114112300815_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;billing-for-wallet-shock-digbijay-mishra-4674632&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674632,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26594,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drug,generic medicine,generic medicines,medicines,Access to Medicines,Access to Healthcare,healthcare,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;     &lt;br /&gt;    At present, only branded drugs are mandated for this in US market&lt;br /&gt;     &lt;br /&gt;    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;     &lt;br /&gt;    Major Indian generic drug firms make at least half their revenue from the US market&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26594,
	&#039;title&#039; =&gt; &#039;Billing for wallet shock -Digbijay Mishra&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;
     &lt;br /&gt;
    At present, only branded drugs are mandated for this in US market&lt;br /&gt;
     &lt;br /&gt;
    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;
     &lt;br /&gt;
    Major Indian generic drug firms make at least half their revenue from the US market
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Business Standard, 24 November, 2014, http://www.business-standard.com/article/companies/billing-for-wallet-shock-114112300815_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;billing-for-wallet-shock-digbijay-mishra-4674632&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674632,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26594
$metaTitle = &#039;LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra&#039;
$metaKeywords = &#039;generic drug,generic medicine,generic medicines,medicines,Access to Medicines,Access to Healthcare,healthcare,Health&#039;
$metaDesc = &#039;
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;     &lt;br /&gt;    At present, only branded drugs are mandated for this in US market&lt;br /&gt;     &lt;br /&gt;    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;     &lt;br /&gt;    Major Indian generic drug firms make at least half their revenue from the US market&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/billing-for-wallet-shock-digbijay-mishra-4674632.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra | Im4change.org</title>
    <meta name="description" content="
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Billing for wallet shock -Digbijay Mishra</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Business Standard</div><p align="justify"><em>Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises</em></p><p align="justify"><em> </em>Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.</p><p align="justify">A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. </p><p align="justify">If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.</p><p align="justify">The move comes after two US legislators' move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy's, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.</p><p align="justify">Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.</p><p align="justify">Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  </p><p align="justify">The probe panel in question said; &quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&quot;</p><p align="justify">The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.</p><p align="justify">&quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&quot; said Senator Sanders.</p><p align="justify">Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. </p><p align="justify">In October, immediately after Prime Minister Narendra Modi's return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India's Sun Pharma and Dr. Reddy's, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.</p><p align="justify">The US drug regulator, the Food &amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. </p><p align="justify">These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi's agenda during his recent visit to the US.</p><p align="justify"><strong>SEDATING PRICES</strong></p><p align="justify"><strong>    </strong>Bill likely to come in US Senate for generic drug makers, such as India's, to pay rebates for federal Medicaid plan<br />     <br />    At present, only branded drugs are mandated for this in US market<br />     <br />    This would be applicable to generic drugs when prices of such medications outpace inflation<br />     <br />    Major Indian generic drug firms make at least half their revenue from the US market</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f37491186a0-trace').style.display = (document.getElementById('cakeErr67f37491186a0-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f37491186a0-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f37491186a0-code').style.display = (document.getElementById('cakeErr67f37491186a0-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f37491186a0-context').style.display = (document.getElementById('cakeErr67f37491186a0-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f37491186a0-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f37491186a0-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26594,
		&#039;title&#039; =&gt; &#039;Billing for wallet shock -Digbijay Mishra&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;
     &lt;br /&gt;
    At present, only branded drugs are mandated for this in US market&lt;br /&gt;
     &lt;br /&gt;
    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;
     &lt;br /&gt;
    Major Indian generic drug firms make at least half their revenue from the US market
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Business Standard, 24 November, 2014, http://www.business-standard.com/article/companies/billing-for-wallet-shock-114112300815_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;billing-for-wallet-shock-digbijay-mishra-4674632&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674632,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26594,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drug,generic medicine,generic medicines,medicines,Access to Medicines,Access to Healthcare,healthcare,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;     &lt;br /&gt;    At present, only branded drugs are mandated for this in US market&lt;br /&gt;     &lt;br /&gt;    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;     &lt;br /&gt;    Major Indian generic drug firms make at least half their revenue from the US market&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26594,
	&#039;title&#039; =&gt; &#039;Billing for wallet shock -Digbijay Mishra&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;
     &lt;br /&gt;
    At present, only branded drugs are mandated for this in US market&lt;br /&gt;
     &lt;br /&gt;
    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;
     &lt;br /&gt;
    Major Indian generic drug firms make at least half their revenue from the US market
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Business Standard, 24 November, 2014, http://www.business-standard.com/article/companies/billing-for-wallet-shock-114112300815_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;billing-for-wallet-shock-digbijay-mishra-4674632&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674632,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26594
$metaTitle = &#039;LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra&#039;
$metaKeywords = &#039;generic drug,generic medicine,generic medicines,medicines,Access to Medicines,Access to Healthcare,healthcare,Health&#039;
$metaDesc = &#039;
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;     &lt;br /&gt;    At present, only branded drugs are mandated for this in US market&lt;br /&gt;     &lt;br /&gt;    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;     &lt;br /&gt;    Major Indian generic drug firms make at least half their revenue from the US market&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/billing-for-wallet-shock-digbijay-mishra-4674632.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra | Im4change.org</title>
    <meta name="description" content="
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Billing for wallet shock -Digbijay Mishra</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Business Standard</div><p align="justify"><em>Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises</em></p><p align="justify"><em> </em>Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.</p><p align="justify">A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. </p><p align="justify">If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.</p><p align="justify">The move comes after two US legislators' move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy's, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.</p><p align="justify">Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.</p><p align="justify">Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  </p><p align="justify">The probe panel in question said; &quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&quot;</p><p align="justify">The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.</p><p align="justify">&quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&quot; said Senator Sanders.</p><p align="justify">Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. </p><p align="justify">In October, immediately after Prime Minister Narendra Modi's return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India's Sun Pharma and Dr. Reddy's, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.</p><p align="justify">The US drug regulator, the Food &amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. </p><p align="justify">These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi's agenda during his recent visit to the US.</p><p align="justify"><strong>SEDATING PRICES</strong></p><p align="justify"><strong>    </strong>Bill likely to come in US Senate for generic drug makers, such as India's, to pay rebates for federal Medicaid plan<br />     <br />    At present, only branded drugs are mandated for this in US market<br />     <br />    This would be applicable to generic drugs when prices of such medications outpace inflation<br />     <br />    Major Indian generic drug firms make at least half their revenue from the US market</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f37491186a0-trace').style.display = (document.getElementById('cakeErr67f37491186a0-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f37491186a0-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f37491186a0-code').style.display = (document.getElementById('cakeErr67f37491186a0-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f37491186a0-context').style.display = (document.getElementById('cakeErr67f37491186a0-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f37491186a0-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f37491186a0-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26594,
		&#039;title&#039; =&gt; &#039;Billing for wallet shock -Digbijay Mishra&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;
     &lt;br /&gt;
    At present, only branded drugs are mandated for this in US market&lt;br /&gt;
     &lt;br /&gt;
    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;
     &lt;br /&gt;
    Major Indian generic drug firms make at least half their revenue from the US market
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Business Standard, 24 November, 2014, http://www.business-standard.com/article/companies/billing-for-wallet-shock-114112300815_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;billing-for-wallet-shock-digbijay-mishra-4674632&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674632,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26594,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic drug,generic medicine,generic medicines,medicines,Access to Medicines,Access to Healthcare,healthcare,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;     &lt;br /&gt;    At present, only branded drugs are mandated for this in US market&lt;br /&gt;     &lt;br /&gt;    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;     &lt;br /&gt;    Major Indian generic drug firms make at least half their revenue from the US market&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26594,
	&#039;title&#039; =&gt; &#039;Billing for wallet shock -Digbijay Mishra&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;
     &lt;br /&gt;
    At present, only branded drugs are mandated for this in US market&lt;br /&gt;
     &lt;br /&gt;
    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;
     &lt;br /&gt;
    Major Indian generic drug firms make at least half their revenue from the US market
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Business Standard, 24 November, 2014, http://www.business-standard.com/article/companies/billing-for-wallet-shock-114112300815_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;billing-for-wallet-shock-digbijay-mishra-4674632&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674632,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26594
$metaTitle = &#039;LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra&#039;
$metaKeywords = &#039;generic drug,generic medicine,generic medicines,medicines,Access to Medicines,Access to Healthcare,healthcare,Health&#039;
$metaDesc = &#039;
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt; &lt;/em&gt;Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The move comes after two US legislators&#039; move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy&#039;s, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The probe panel in question said; &amp;quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&amp;quot; said Senator Sanders.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In October, immediately after Prime Minister Narendra Modi&#039;s return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India&#039;s Sun Pharma and Dr. Reddy&#039;s, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The US drug regulator, the Food &amp;amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi&#039;s agenda during his recent visit to the US.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;SEDATING PRICES&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;strong&gt;    &lt;/strong&gt;Bill likely to come in US Senate for generic drug makers, such as India&#039;s, to pay rebates for federal Medicaid plan&lt;br /&gt;     &lt;br /&gt;    At present, only branded drugs are mandated for this in US market&lt;br /&gt;     &lt;br /&gt;    This would be applicable to generic drugs when prices of such medications outpace inflation&lt;br /&gt;     &lt;br /&gt;    Major Indian generic drug firms make at least half their revenue from the US market&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/billing-for-wallet-shock-digbijay-mishra-4674632.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra | Im4change.org</title>
    <meta name="description" content="
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Billing for wallet shock -Digbijay Mishra</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Business Standard</div><p align="justify"><em>Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises</em></p><p align="justify"><em> </em>Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.</p><p align="justify">A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. </p><p align="justify">If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.</p><p align="justify">The move comes after two US legislators' move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy's, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.</p><p align="justify">Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.</p><p align="justify">Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  </p><p align="justify">The probe panel in question said; &quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&quot;</p><p align="justify">The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.</p><p align="justify">&quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&quot; said Senator Sanders.</p><p align="justify">Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. </p><p align="justify">In October, immediately after Prime Minister Narendra Modi's return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India's Sun Pharma and Dr. Reddy's, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.</p><p align="justify">The US drug regulator, the Food &amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. </p><p align="justify">These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi's agenda during his recent visit to the US.</p><p align="justify"><strong>SEDATING PRICES</strong></p><p align="justify"><strong>    </strong>Bill likely to come in US Senate for generic drug makers, such as India's, to pay rebates for federal Medicaid plan<br />     <br />    At present, only branded drugs are mandated for this in US market<br />     <br />    This would be applicable to generic drugs when prices of such medications outpace inflation<br />     <br />    Major Indian generic drug firms make at least half their revenue from the US market</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 26594,
		'title' => 'Billing for wallet shock -Digbijay Mishra',
		'subheading' => '',
		'description' => '<div align="justify">
-Business Standard
</div>
<p align="justify">
<em>Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises</em>
</p>
<p align="justify">
<em> </em>Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.
</p>
<p align="justify">
A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. 
</p>
<p align="justify">
If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.
</p>
<p align="justify">
The move comes after two US legislators' move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy's, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.
</p>
<p align="justify">
Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.
</p>
<p align="justify">
Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  
</p>
<p align="justify">
The probe panel in question said; &quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&quot;
</p>
<p align="justify">
The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.
</p>
<p align="justify">
&quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&quot; said Senator Sanders.
</p>
<p align="justify">
Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. 
</p>
<p align="justify">
In October, immediately after Prime Minister Narendra Modi's return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India's Sun Pharma and Dr. Reddy's, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.
</p>
<p align="justify">
The US drug regulator, the Food &amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. 
</p>
<p align="justify">
These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi's agenda during his recent visit to the US.
</p>
<p align="justify">
<strong>SEDATING PRICES</strong>
</p>
<p align="justify">
<strong>    </strong>Bill likely to come in US Senate for generic drug makers, such as India's, to pay rebates for federal Medicaid plan<br />
     <br />
    At present, only branded drugs are mandated for this in US market<br />
     <br />
    This would be applicable to generic drugs when prices of such medications outpace inflation<br />
     <br />
    Major Indian generic drug firms make at least half their revenue from the US market
</p>',
		'credit_writer' => 'Business Standard, 24 November, 2014, http://www.business-standard.com/article/companies/billing-for-wallet-shock-114112300815_1.html',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'billing-for-wallet-shock-digbijay-mishra-4674632',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4674632,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 26594,
	'metaTitle' => 'LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra',
	'metaKeywords' => 'generic drug,generic medicine,generic medicines,medicines,Access to Medicines,Access to Healthcare,healthcare,Health',
	'metaDesc' => '
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme...',
	'disp' => '<div align="justify">-Business Standard</div><p align="justify"><em>Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises</em></p><p align="justify"><em> </em>Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.</p><p align="justify">A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. </p><p align="justify">If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.</p><p align="justify">The move comes after two US legislators' move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy's, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.</p><p align="justify">Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.</p><p align="justify">Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  </p><p align="justify">The probe panel in question said; &quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&quot;</p><p align="justify">The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.</p><p align="justify">&quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&quot; said Senator Sanders.</p><p align="justify">Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. </p><p align="justify">In October, immediately after Prime Minister Narendra Modi's return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India's Sun Pharma and Dr. Reddy's, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.</p><p align="justify">The US drug regulator, the Food &amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. </p><p align="justify">These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi's agenda during his recent visit to the US.</p><p align="justify"><strong>SEDATING PRICES</strong></p><p align="justify"><strong>    </strong>Bill likely to come in US Senate for generic drug makers, such as India's, to pay rebates for federal Medicaid plan<br />     <br />    At present, only branded drugs are mandated for this in US market<br />     <br />    This would be applicable to generic drugs when prices of such medications outpace inflation<br />     <br />    Major Indian generic drug firms make at least half their revenue from the US market</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 26594,
	'title' => 'Billing for wallet shock -Digbijay Mishra',
	'subheading' => '',
	'description' => '<div align="justify">
-Business Standard
</div>
<p align="justify">
<em>Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises</em>
</p>
<p align="justify">
<em> </em>Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.
</p>
<p align="justify">
A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. 
</p>
<p align="justify">
If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.
</p>
<p align="justify">
The move comes after two US legislators' move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy's, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.
</p>
<p align="justify">
Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.
</p>
<p align="justify">
Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  
</p>
<p align="justify">
The probe panel in question said; &quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&quot;
</p>
<p align="justify">
The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.
</p>
<p align="justify">
&quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&quot; said Senator Sanders.
</p>
<p align="justify">
Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. 
</p>
<p align="justify">
In October, immediately after Prime Minister Narendra Modi's return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India's Sun Pharma and Dr. Reddy's, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.
</p>
<p align="justify">
The US drug regulator, the Food &amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. 
</p>
<p align="justify">
These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi's agenda during his recent visit to the US.
</p>
<p align="justify">
<strong>SEDATING PRICES</strong>
</p>
<p align="justify">
<strong>    </strong>Bill likely to come in US Senate for generic drug makers, such as India's, to pay rebates for federal Medicaid plan<br />
     <br />
    At present, only branded drugs are mandated for this in US market<br />
     <br />
    This would be applicable to generic drugs when prices of such medications outpace inflation<br />
     <br />
    Major Indian generic drug firms make at least half their revenue from the US market
</p>',
	'credit_writer' => 'Business Standard, 24 November, 2014, http://www.business-standard.com/article/companies/billing-for-wallet-shock-114112300815_1.html',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'billing-for-wallet-shock-digbijay-mishra-4674632',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4674632,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 26594
$metaTitle = 'LATEST NEWS UPDATES | Billing for wallet shock -Digbijay Mishra'
$metaKeywords = 'generic drug,generic medicine,generic medicines,medicines,Access to Medicines,Access to Healthcare,healthcare,Health'
$metaDesc = '
-Business Standard


Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises


 Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme...'
$disp = '<div align="justify">-Business Standard</div><p align="justify"><em>Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises</em></p><p align="justify"><em> </em>Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation.</p><p align="justify">A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. </p><p align="justify">If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world.</p><p align="justify">The move comes after two US legislators' move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy's, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times.</p><p align="justify">Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation.</p><p align="justify">Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers.  </p><p align="justify">The probe panel in question said; &quot;Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits.&quot;</p><p align="justify">The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing.</p><p align="justify">&quot;Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry,&quot; said Senator Sanders.</p><p align="justify">Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. </p><p align="justify">In October, immediately after Prime Minister Narendra Modi's return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India's Sun Pharma and Dr. Reddy's, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market.</p><p align="justify">The US drug regulator, the Food &amp; Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. </p><p align="justify">These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi's agenda during his recent visit to the US.</p><p align="justify"><strong>SEDATING PRICES</strong></p><p align="justify"><strong>    </strong>Bill likely to come in US Senate for generic drug makers, such as India's, to pay rebates for federal Medicaid plan<br />     <br />    At present, only branded drugs are mandated for this in US market<br />     <br />    This would be applicable to generic drugs when prices of such medications outpace inflation<br />     <br />    Major Indian generic drug firms make at least half their revenue from the US market</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Billing for wallet shock -Digbijay Mishra

-Business Standard Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation. A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner when drug makers raise prices at a rate higher than inflation. At present, only branded drug manufacturers pay a rebate to Medicaid. If such a legislation is passed, it would impact all major Indian generic drug firms, which make at least half their revenue from generic drug sales in the US, the largest drug market in the world. The move comes after two US legislators' move to probe steep price increases by generic drug makers, including Sun Pharma and Dr Reddy's, in the US. A hearing of a Senate panel subcommittee on primary health and ageing was called on Thursday this week after a member each of the Senate (Bernie Sanders) and of the other chamber, the House of Representatives (Elijah Cummings) announced were investigating why some generic drug prices had risen hundreds to thousands of percentage points in recent times. Sanders also said he was introducing a Bill that would require generic drug makers to pay a rebate to Medicaid if their cost increased faster than inflation. Usually, generic drugs are cheaper than patented ones but a price rise in the former of 390-8,200 per cent has brought the lens over the manufacturers. The probe panel in question said; "Some companies are exploiting monopolies and disruptions in supply to implement massive price increases in order to reap unconscionable profits." The chief executives of three drug makers - Illinois-based Marathon Pharmaceuticals and the Pennsylvania-headquartered Lannett Co and Teva Pharmaceutical Industries - refused to testify at the hearing. "Drug companies have seen the opportunity to make a whole lot of money and they are seizing that opportunity. This is greed at work in the pharmaceutical industry," said Senator Sanders. Medicaid is a programme in the US specially focused on the poor, for access to medicines at a cheaper rate. The lower prices of generic drugs make these the first choice for both patients and insurers. Generic drugs account for roughly 85 per cent of all medicines dispensed in the US, according to IMS Health. Typically, generic drug prices fall as more companies begin offering competing versions of the same drug. In October, immediately after Prime Minister Narendra Modi's return from the US, the panel in question of the US Congress initiated its probe. It wrote letters to around 14 drug firms, including India's Sun Pharma and Dr. Reddy's, initiating investigation and seeking details about the extraordinary price increases in several generic products available in the US market. The US drug regulator, the Food & Drug Administration (FDA), has also been tightening the noose over the quality of generic drugs being manufactured by domestic pharma companies in India, with a series of surprise inspections and import alerts. Several manufacturing plants of leading domestic companies, such as Ranbaxy, Sun Pharma, Wockhardt and Strides Arcolab, have come under the FDA scanner for compliance issues. These developments come at a time when there is conflict of opinion between India and the US over issues such as intellectual property and these increasing regulatory enforcements by the FDA on Indian companies. Issues entailing intellectual property rights, especially with reference to pharmaceuticals and information technology, were top on the list of Modi's agenda during his recent visit to the US. SEDATING PRICES Bill likely to come in US Senate for generic drug makers, such as India's, to pay rebates for federal Medicaid plan At present, only branded drugs are mandated for this in US market This would be applicable to generic drugs when prices of such medications outpace inflation Major Indian generic drug firms make at least half their revenue from the US market